Sascha A Tuchman
Overview
Explore the profile of Sascha A Tuchman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jensen C, Deal A, Srikanth S, Nyrop K, Mitin N, LeBlanc M, et al.
J Geriatr Oncol
. 2024 Dec;
:102174.
PMID: 39706780
No abstract available.
2.
LeBlanc M, Zhou X, Baggett C, Tuchman S, Jensen C, Lichtman E, et al.
Clin Lymphoma Myeloma Leuk
. 2024 May;
24(9):611-620.
PMID: 38760283
Introduction: The therapeutic landscape in relapsed/refractory multiple myeloma (RRMM) has changed rapidly, with twenty-two drug approvals since 2012. We characterized population-level trends in RRMM therapy selection, survival and cost outcomes...
3.
Jensen C, Deal A, Nyrop K, Logan M, Mangieri N, Strayhorn M, et al.
J Geriatr Oncol
. 2023 Dec;
15(2):101680.
PMID: 38104482
Introduction: Geriatric assessment (GA)-guided supportive care programs have been successful in improving treatment outcomes for older adults with solid-organ cancers. This study aimed to evaluate the feasibility of a GA-guided...
4.
Gertz M, Abonour R, Gibbs S, Finkel M, Landau H, Lentzsch S, et al.
Clinicoecon Outcomes Res
. 2023 Sep;
15:673-680.
PMID: 37719133
Purpose: Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity...
5.
Schiller G, Lipe B, Bahlis N, Tuchman S, Bensinger W, Sutherland H, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Jul;
23(9):e286-e296.e4.
PMID: 37393120
Background: The increasing use of anti-CD38 monoclonal antibodies (αCD38 mAbs) for newly diagnosed or early relapsed multiple myeloma (MM), especially in non-transplant eligible patients, may lead to more patients developing...
6.
Grant S, Jansen M, Kuo T, Rubinstein S, Wildes T, Tuchman S, et al.
JCO Oncol Pract
. 2022 Dec;
19(2):e248-e262.
PMID: 36473128
Purpose: Residents of communities facing social vulnerability (eg, poverty) have limited access to clinical trials, leaving them susceptible to experiencing poor health outcomes. We examined the association between North Carolina...
7.
Baljevic M, Gasparetto C, Schiller G, Tuchman S, Callander N, Lentzsch S, et al.
EJHaem
. 2022 Dec;
3(4):1270-1276.
PMID: 36467792
There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy...
8.
Kang Y, Sundaramoorthy P, Gasparetto C, Feinberg D, Fan S, Long G, et al.
Ann Hematol
. 2022 Dec;
102(2):369-383.
PMID: 36460794
Multiple myeloma (MM) remains an incurable disease and there is an unmet medical need for novel therapeutic drugs that do not share similar mechanisms of action with currently available agents....
9.
Yusuf A, Heiling H, Deal A, Jensen C, Mangieri N, Nyrop K, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Sep;
22(12):920-927.
PMID: 36085276
Background: Cancer-related cognitive impairment (CRCI) has been largely unstudied in patients with multiple myeloma (MM). This study describes patient-reported cognition over time and patient factors associated with adverse cognitive outcomes...
10.
Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Jensen C, Byku M, Hladik G, Jain K, Traub R, Tuchman S
Front Oncol
. 2022 Jul;
12:907584.
PMID: 35814419
Immunoglobulin light chain (AL) amyloidosis is a disorder of clonal plasma cells characterized by deposition of amyloid fibrils in a variety of tissues, leading to end-organ injury. Renal or cardiac...